Srinivas Vourganti to Xenograft Model Antitumor Assays
This is a "connection" page, showing publications Srinivas Vourganti has written about Xenograft Model Antitumor Assays.
Connection Strength
0.051
-
Epidermal Growth Factor Receptor (EGFR)-targeted Photoimmunotherapy (PIT) for the Treatment of EGFR-expressing Bladder Cancer. Mol Cancer Ther. 2017 10; 16(10):2201-2214.
Score: 0.037
-
Experimental treatment of Epstein-Barr virus-associated primary central nervous system lymphoma. Cancer Res. 2003 Mar 01; 63(5):965-71.
Score: 0.014